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The introduction of more efficacious treatments for diabetic
kidney disease may slow its progression, but evidence for
their effectiveness in populations is sparse. We examined
trends in the incidence of clinical proteinuria, defined as a
urinary protein-to-creatinine ratio 40.5 g/g, and diabetic
end-stage renal disease (ESRD), defined as death from
diabetic nephropathy or onset of dialysis, in Pima Indians
with type 2 diabetes between 1967 and 2002. The study
included 2189 diabetic subjects X25 years old. During
follow-up, 366 incident cases of proteinuria occurred in the
subset of 1715 subjects without proteinuria at baseline. The
age–sex-adjusted incidence rate of proteinuria increased
from 24.3 cases/1000 person-years (pyrs) (95% confidence
interval (CI) 18.7–30.0) in 1967–1978 to 35.4 cases/1000 pyrs
(95% CI 28.1–42.8) in 1979–1990 and 38.9 cases/1000 pyrs
(95% CI 31.2–46.5) in 1991–2002 (Ptrendo0.0002). In each
period, the age–sex-adjusted incidence of proteinuria
increased with diabetes duration, but diabetes duration-
specific incidence was stable throughout the study period
(P¼ 0.8). The age–sex-adjusted incidence of ESRD increased
between 1967 and 1990 and declined thereafter. The
incidence of proteinuria increased over 36 years in Pima
Indians as the proportion of people with diabetes of long
duration increased. On the other hand, the incidence of ESRD
declined after 1990, coinciding with improved control of
blood pressure, hyperglycemia, and perhaps other risk
factors.
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Increased urinary protein excretion in the presence of
diabetes is an indicator of diabetic nephropathy, the leading
cause of kidney failure in the United States and other
developed countries.1 In addition to being a risk factor for
kidney failure, proteinuria is a risk factor for cardiovascular
disease in diabetic and non-diabetic persons. The likelihood
of progression to end-stage renal disease (ESRD) in those
with diabetes is determined primarily by the duration of
diabetes and other risk factors associated with diabetes, such
as hyperglycemia, hypertension, and ethnicity. Certain ethnic
groups, including African Americans, Hispanics, and Native
Americans, develop type 2 diabetes at younger ages than
Caucasians2,3 and are particularly predisposed to kidney
disease as a complication of diabetes.
In this study, we examined trends in the incidence rates of
clinical proteinuria and ESRD in type 2 diabetic Pima
Indians from the Gila River Indian Community in Arizona
and identified factors that might influence development of
proteinuria and its progression to ESRD. Diabetes in Pima
Indians is entirely type 2 and it is characterized by the lack of
insulin dependence,3 absent or low titers of islet cell4 and
glutamic acid decarboxylase (GAD) antibodies,5 and absence
of linkage or strong association with maturity onset diabetes
in youth (MODY) loci.6,7
RESULTS
Among the 1715 type 2 diabetic subjects (577 men and 1138
women) without proteinuria at baseline, 366 incident cases of
proteinuria occurred during a median follow-up ranging
from 4.7 to 6.5 years. Eighty-eight cases occurred in the first
period, 137 in the second, and 141 in the third time period.
Baseline clinical and demographic characteristics of the
subjects in the three time periods are shown in Table 1.
Mean age at onset of diabetes declined and mean duration of
diabetes increased following the first time period. Baseline
mean arterial pressure, serum cholesterol concentration, and
2-h plasma glucose concentration were lower in the second
and third periods than in the first, whereas baseline body
mass index was higher.
The age–sex-adjusted incidence rate of proteinuria in-
creased from 24.3 cases/1000 person-years (pyrs) (95%
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2006 International Society of Nephrology
Received 22 February 2006; revised 7 August 2006; accepted 15 August
2006; published online 27 September 2006
Correspondence: ME Pavkov, Diabetes Epidemiology and Clinical Research
Section, National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health, 1550 East Indian School Road, Phoenix, Arizona
85014-4972, USA. E-mail: mpavkov@phx.niddk.nih.gov
1840 Kidney International (2006) 70, 1840–1846
confidence interval (CI) 18.7–30.0) in 1967–1978 to
35.4 cases/1000 pyrs (95% CI 28.1–42.8) in 1979–1990 and
38.9 cases/1000 pyrs (95% CI 31.2–46.5) in 1991–2002
(Ptrendo0.0002). The greatest increase occurred during the
second period (incidence rate ratios (IRRs) relative to the
first period¼ 1.6, 95% CI 1.2–2.1) and the incidence rate
stabilized thereafter (IRR relative to the first period¼ 1.7,
95% CI 1.3–2.2). In each time period, the unadjusted and
age–sex-adjusted incidence rates of proteinuria increased
substantially with increasing duration of diabetes (Table 2).
Moreover, the proportion of person-years accumulated in the
longer diabetes duration category increased after the first
time period, reflecting an increase in the number of subjects
with diabetes of long duration. The fraction of person-years
of follow-up among persons with X10 year’s duration of
diabetes was 26% in the first time period, 44% in the second,
and 40% in the third time period. After additional
adjustment for diabetes duration, there was no change in
proteinuria incidence during the second (IRR¼ 1.1, 95% CI
0.8–1.4) and third (IRR¼ 1.2, 95% CI 0.9–1.5) time periods,
relative to the first.
Hypertension was present in 77% of the diabetic subjects
at the midpoint of the first time period, 68% of those in the
second time period, and 71% of those in the third time
period. More subjects received antihypertensive medicines
during the third period (prevalence at midpoint of the period
was 42%), than in the previous periods (prevalence at
midpoint of first and second period was 19 and 24%,
respectively). Figure 1 shows prevalence of antihypertensive
medicine use among the diabetic subjects at the midpoint
of nine 4-year time periods. Intervention to block the
renin–angiotensin system (RAS; angiotensin-converting
enzyme inhibitors (ACEis) and angiotensin receptor antago-
nists (angiotensin receptor blockers)) was widely used among
those receiving antihypertensive treatment in the 1990s. By
the end of 2002, 75% of the people taking any antihyperten-
sive medicines took RAS inhibitors.
Among the 2189 type 2 diabetic subjects (905 men and
1284 women) included in the study, 371 developed diabetic
ESRD. Figure 2a shows the age–sex-adjusted incidence rates
of ESRD, including dialysis and deaths from diabetic
nephropathy, for 4-year intervals between 1967 and 2002.
Dialysis was not widely available up to the mid 1970s, so
most persons who developed kidney failure in this time
period died without receiving dialysis. As availability of
Table 1 | Baseline clinical and demographic characteristics of
diabetic Pima Indians included in the three independent time
periods and without proteinuria at baseline
Time period
1967–1978 1979–1990 1991–2002
N 509 557 649
Men 196 173 208
Women 313 384 441
Median follow-up
(range) (years)
6.5
(1.3–11.7)
5.7
(1.4–11.8)
4.7
(1.5–11.7)
Age (years) 46.670.6 46.170.5 43.670.5
Diabetes duration (years) 3.670.2 6.370.3 6.370.3
Age at onset of diabetes
(years)
43.070.6 39.870.5 37.370.4
Age at onset of proteinuria
(years)
53.471.5 54.771.0 49.470.9
Mean arterial pressure
(mm Hg)
101.870.7 91.170.5 91.870.5
Serum creatinine (mmol/l) 63.670.6 61.970.5 63.670.5
BMI (kg/m2)
Men 31.370.5 30.970.5 34.770.5
Women 33.670.4 33.870.4 37.370.4
2-h plasma glucose (mmol/l) 18.870.3 18.270.3 16.770.3
Serum cholesterol (mmol/l) 4.870.05 4.670.04 4.670.04
BMI, body mass index.
Values represent mean7s.e.
Table 2 | Incidence rate of proteinuria by diabetes duration, proportion of pyrs accumulating in short and long duration
categories, and unadjusted and age–sex-adjusted incidence rates among all diabetic Pima Indians in three independent
time periods
Time period
1967–1978 1979–1990 1991–2002
Cases Pyrs Ratea Cases Pyrs Ratea Cases Pyrs Ratea
Diabetes duration (years)
o10 31 2383.8 13.0 22 1846.2 11.9 32 2055.9 15.6
10–15 32 598.6 53.5 36 712.3 50.5 31 620.2 50.0
15–20 17 176.9 96.1 47 493.0 95.3 48 439.6 109.2
X20 8 78.7 101.6 32 231.5 138.2 30 295.4 101.6
Unadjusted rate 88 3238.0 27.2 137 3283.0 41.7 141 3411.1 41.3
Age–sex-adjusted rate 24.3 35.4 38.9
(95% CI) (18.7–30.0) (28.1–42.8) (31.2–46.5)
Proportion of person-years of follow-up
in subjects with X10 years duration
of diabetes (%)
26 44 40
CI, confidence interval; pyrs, person-years.
aRate is reported as cases per 1000 pyrs at risk.
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Figure 1 | Proportion of diabetic Pima Indians taking antihypertensive and RAS inhibitor treatment in each time period. Estimates were
computed from self-report at the research examination closest to the midpoint of each 4-year time period. HTMED¼ any antihypertensive
medicines, RAS¼ACEi or angiotensin blocking agent. Complete data on RAS medicines were available starting with the time period 1995–1998,
so prevalence of the medicines is shown from this period forward. From 1995 onward, the combined height of the two bars represents the
total percent of persons taking any antihypertensive medicines.
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Figure 2 | Incidence rates of ESRD, defined by deaths from diabetic nephropathy (DN) and renal replacement therapy (RRT), in type 2
diabetic Pima Indians X25 years old. (a) Age–sex-adjusted incidence rates are calculated for 4-year intervals between 1967 and 2002.
The number on top of each bar represents new cases of ESRD. The combined height of the two bars represents the total incidence of ESRD.
(b) Sex-adjusted incidence of diabetic ESRD for nine 4-year intervals, by age group.
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dialysis services increased in later years, so did its utilization.
The age–sex-adjusted incidence of diabetic ESRD generally
increased between 1967 and 1990 (Ptrend¼ 0.006). Starting
with 1990, a decline in diabetic ESRD rates was noted
(Ptrend¼ 0.0003), although the overall rate during the 1990s
remained higher than in the previous decade. The decline in
ESRD incidence after 1990 remained after additional
adjustment for duration of diabetes (Ptrend¼ 0.0002), which
was longer, on average, than in previous time periods and
despite a higher incidence rate of proteinuria than in
previous time periods. The age–sex-adjusted incidence of
diabetic ESRD declined in subjects aged 45 years and older
(Ptrend¼ 0.0002), but not among the younger diabetic
subjects (Ptrend¼ 0.76) (Figure 2b). A similar decline in
ESRD rates was found even when the 21 cases of ESRD owing
to causes other than diabetes were included in the analysis
(data not shown).
DISCUSSION
The incidence rate of proteinuria increased among diabetic
Pima Indians over 36 years. The increase was due primarily
to an increase in the proportion of subjects with diabetes of
long duration, as the incidence as a function of duration
remained relatively stable over the years. On the other hand,
after 1990 the incidence of diabetic ESRD declined. This
decline, mostly among middle-aged and older Pima Indians,
coincided with expansion in the use of medicines for blood
pressure, lipid, and glycemic control and with the introduc-
tion and widespread use within the community of new
hypoglycemic medicines and medicines that block the RAS.8
These interventions appear to have contributed to a sustained
improvement in risk factors for diabetes-related ESRD,
including blood pressure, serum cholesterol, and plasma
glucose concentrations. Whether one or more of these factors
are responsible for the recent decline in ESRD incidence
cannot be determined with certainty in this observational
study.
In a previous study covering the period from 1955 to 1994
in the same population, the incidence rates of proteinuria
increased nearly twofold in more recent birth cohorts,9 owing
to the longer average duration of diabetes in the later periods,
consistent with the present findings. Major changes in
incidence rates were found only after considering additional
proteinuria risk factors in multivariate analyses. Other
factors, such as exposure to diabetes in utero,10 familial
aggregation of kidney disease,11 parental blood pressure,12
and higher prediabetic blood pressure13 also increase the risk
of proteinuria in Pima Indians.
Clinical trials indicate that ACEi and angiotensin receptor
blockers slow the progression from micro- to macroalbumi-
nuria, increase the rate of regression from micro- to
normoalbuminuria, preserve the glomerular filtration rate,
and control hypertension in people with diabetes.14–17
Moreover, the effect is present regardless of the type of
diabetes, stage of diabetic nephropathy, and duration of
treatment.18,19 A recent meta-analysis disputes the specific
renoprotective effect of these medicines, concluding that RAS
inhibition with either ACEi or angiotensin receptor blockers
is not more effective at preventing progressive kidney disease
than other antihypertensive agents in persons with diabetes.20
However, the studies selected for the meta-analysis included
primarily diabetic patients who did not have clinical
proteinuria and who had well-preserved kidney function.
In the Pima Indians, therapeutic intervention to block the
RAS was introduced in November 1986, with only limited use
until September 1989.21 Subsequently, their use increased
gradually, as did the use of combination therapy for diabetes
and blood pressure control.8 To what extent increased use of
RAS inhibition among the Pima Indians contributed to the
decline in ESRD incidence cannot be determined from this
study, but most clinical trial data support a role for these
agents in delaying the progression of kidney disease.14–19
A decline in diabetic ESRD has also been noted in other
diabetic populations. Among Southwestern American In-
dians, including Pima Indians, residing in Arizona, Colorado,
Nevada, New Mexico, and Utah, the incidence rate of diabetic
ESRD in all age groups declined between 1993 and 2001.22
The increasing use of RAS inhibitors among diabetic
American Indians and a reduction in risk factors for
diabetes-related ESRD were proposed as factors contributing
to the decline in ESRD incidence in these populations. On
the other hand, increasing prevalence of cardiovascular
disease mortality among American Indians could reduce
the number of those surviving to develop ESRD. Among
diabetic Pima Indians, cardiovascular disease mortality rates
increased markedly after the start of dialysis.23,24 Among
diabetic Pima Indians not receiving dialysis, however, death
rates attributable to cardiovascular disease changed little over
time. Therefore, we believe that changes in cardiovascular
mortality in this population did not contribute to the recent
decline in the incidence rate of ESRD. In the US diabetic
population, the incidence of treatment for diabetic ESRD
declined in 1997, and then leveled off.25 The decline was most
evident in young white patients.26 These studies included
only treated patients reported to the Centers for Medicare
and Medicaid Services, and did not include patients who died
of ESRD without receiving renal replacement therapy.
By contrast to the US diabetic population, the decline in
incidence of diabetic ESRD in the Pima Indians was primarily
in those X45 years old. The lack of decline in the incidence
of ESRD in diabetic Pima Indians aged 25–44 years was
associated with a lower percentage of RAS inhibitor usage
than in older subjects (13% compared with 21%). Women of
childbearing age were least likely to receive RAS inhibitors,
presumably because of concerns about use of ACEi or
angiotensin receptor blockers during pregnancy. In addition,
RAS inhibitors have only recently been approved for
treatment of hypertension and diabetic nephropathy in
children and adolescents,27–29 so their usage may not have
been sufficient to have an impact on ESRD in young subjects.
Even though the proportion of youth developing diabetes
among the Pima and in the general US population is small,30
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the current epidemic of obesity in this age group is already
associated with an increasing incidence of diabetes in
childhood and adolescence.31 This factor may, in turn,
reverse the overall decline in diabetic ESRD, if efforts are not
concentrated in preventing or delaying the onset of diabetes
in children.
In the present study, proteinuria was ascertained at
research examinations. Accordingly, the incidence of protein-
uria was determined independently in the three time periods,
so person-time at risk was counted the same way in each
period. If the time periods had not been considered
independently and person-time was counted to the end of
each time period, with the exception of the last period, in
which it would be counted only to the last examination, an
overestimate of the incidence rate of proteinuria in the final
period would have occurred. Independent time periods were
not required for computing ESRD incidence, as this outcome
was ascertained independently of the research examinations.
The number of subjects followed in the proteinuria analysis
was less than in the ESRD analysis because subjects were
excluded from the proteinuria analysis if they did not have at
least two examinations during a 12-year time period or if
they were prevalent cases of proteinuria. Consequently, the
number of subjects that progressed to ESRD was greater than
the number that progressed to proteinuria.
Onset and duration of diabetes are determined more
precisely in Pima Indians than in other populations, owing to
periodic glucose tolerance testing since 1965. Nevertheless,
because diabetes diagnosed before 1965 was not as well
documented in this population, duration of diabetes may be
underestimated to a greater extent in the first time period of
the study. If true duration in the first period was indeed
greater than we estimated, then the true duration-specific
incidence rate of proteinuria in the first period would be
lower, and the true duration-specific incidence rates of
proteinuria might have increased between the first and
second periods.
Conclusion
The incidence rate of proteinuria among Pima Indians
increased over the past 36 years as the proportion of those
with diabetes of long duration increased. In those of similar
age, sex, and duration of diabetes, the incidence remained
largely unchanged during the course of this study despite
improvement in blood pressure and glycemic control.
Progression to ESRD, however, declined, suggesting that
newer treatments for diabetic kidney disease, although not
preventing the development of kidney disease, may slow its
progression. More effective treatments to prevent diabetic
kidney disease, particularly in the young diabetic population,
may be required if we are to control the worldwide pandemic
of diabetic kidney disease.
MATERIALS AND METHODS
The Pima Indians and the closely related Tohono O’odham
(Papago) Indians who live in the Gila River Indian Community in
Arizona participate in a longitudinal study of diabetes and its
complications. Since 1965, each member of this community who is
X5 years old is invited to have a research examination approxi-
mately every 2 years, regardless of health. These biennial examina-
tions include measurements of venous plasma glucose
concentration, obtained 2 h after a 75 g oral glucose load, and
assessment for the complications of diabetes. Fasting plasma glucose
concentration was also measured at some of the examinations.
Protein and creatinine concentrations are measured in urine
specimens collected at the end of the 2-h glucose tolerance test.
Among those with at least a trace of protein in the urine by dipstick,
the concentration is determined quantitatively by the Shevky–Staf-
ford method.32 Serum and urine creatinine concentrations are
measured by a modification of the Jaffe´ reaction.33 In this analysis,
proteinuria was defined by a protein-to-creatinine ratio
(PCR)X0.5 g protein/g creatinine, reflecting an estimated protein
excretion rate of at least 0.5 g/day. Diabetes was diagnosed by 1985
World Health Organization criteria34 (fasting plasma glucose
X7.8 mmol/l or 2 h post-load plasma glucose X11.1 mmol/l). Only
the 2-h post-load plasma glucose concentration was used to
diagnose diabetes at the research examinations, as this measurement
was available throughout the study period. The date of diagnosis
was determined from these research examinations or from review of
clinical records if diabetes was diagnosed in the course of routine
medical care. Hypertension was defined according to the Seventh
Report of the Joint National Committee on Detection, Evaluation
and Treatment of High Blood Pressure35 recommendations for
diabetic subjects as a systolic blood pressure X130 mm Hg, a
diastolic blood pressure X80 mm Hg, or treatment with anti-
hypertensive medicine. Mean arterial pressure was calculated as 2/3
of the diastolic arterial pressureþ 1/3 of the systolic arterial
pressure. ESRD was defined as initiation of chronic dialysis or
death from diabetic nephropathy if dialysis was not available or
refused and was ascertained independently of the research
examinations. The cause of kidney failure in those receiving dialysis
was ascertain by review of clinical records. The nephrologists
treating the patients determined indications for dialysis and data on
specific indications were not gathered as part of this study. Deaths
were attributed to diabetic nephropathy if the ICD-9 code 250.4 was
specified as the underlying or a contributing cause of death. The
causes of death were determined by review of clinical records,
autopsy reports, and death certificates. The study population
included 2189 subjects who were at least half Pima or Tohono
O’odham heritage, resided in the community during a time period,
were examined when at least 25 years of age and had diabetes.
Statistical analysis
Incidence rates of proteinuria were computed independently in
three 12-year time periods (January 1967 through December 1978;
January 1979 through December 1990; January 1991 through
December 2002) as the number of new cases of proteinuria per
1000 pyrs at risk. New cases of proteinuria were defined by the first
occurrence of a PCR X0.5 g/g in subjects with at least one previous
diabetic research examination during the same period at which PCR
was below this value. Subjects were included in a time period if they
resided in the community at any time during that period. Follow-up
extended from the date of the first diabetic research examination
after the age of 25 years to development of proteinuria or, in those
who did not develop proteinuria, to the date of the last research
examination within the same time period. Subjects were included in
the time periods in which they had at least two eligible research
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examinations. Accordingly, 200 subjects from the first time period
were included in the second and 38 subjects from the first and 184
from the second period were included in the third. As the incidence
of proteinuria was considered independently in each time period, it
was possible for a subject to be considered an incident case in more
than one time period if a PCRX0.5 g/g in one time period reverted
to a PCR o 0.5 g/g in a subsequent period. Three cases occurred in
both the first and second time periods and six cases occurred in both
the second and third periods. No subject was considered a case in
both the first and the third time periods.
Age–sex-adjusted incidence rates of proteinuria were externally
standardized to the 1985 Pima Indian population, aged 25 years and
older. Age–sex- and age–sex–diabetes duration-adjusted IRR
were examined for the three time periods. Because external
standardization for age, sex, and duration would result in some
strata being too small for reliable estimates, all IRRs were computed
by internal standardization,36 a method that yields slightly different
results than an externally standardized IRR. Tests for general
association were computed by the Mantel–Haenszel test37 and for
linear association by the Mantel extension test,38 modified for
person-time denominators.39 Data are presented as means7s.e. or
medians (ranges).
Incidence rates of diabetic ESRD were computed in 2189 subjects
for nine 4-year intervals from 1967 through 2002 as the number of
cases per 1000 pyrs at risk. In computing ESRD incidence, research
examinations were not required within each time period because
ESRD was ascertained independently of these examinations, and
subjects were included regardless of their baseline proteinuria.
Person-time accumulated from the first diabetic examination after
the age of 25 years until an event (death from diabetic nephropathy
or initiation of dialysis), death from other causes, or December
2002, whichever came earlier. For 21 subjects who developed ESRD
owing to causes other than diabetes, follow-up ended when dialysis
began. For each 4-year interval, the numerator represented the
number of ESRD cases and the denominator the number of person-
years accumulated during the 4-year interval, and included subjects
who ever resided in the community during the time interval.
Prevalence of antihypertensive treatment was computed in
diabetic persons who were not on dialysis without regard to the
level of proteinuria. Estimates were computed for the three 12-year
time intervals and for nine 4-year intervals as the proportion of
subjects who were receiving these medicines at the research
examination closest to the midpoint of these intervals. Treatment
was assessed from self-report of subjects at each research examina-
tion. Complete data on specific classes of antihypertensive medicines
were available beginning with the time period 1995–1998, so the
prevalence of treatment with RAS inhibitors was computed from
this time period forward.
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